Abbott Laboratories
Manufacturer Details
There are currently no manufacturer details available.
Share This Page
Abbott Laboratories Drugs
Orocam
Always provide the client information sheet with prescription. Carefully consider the potential benefits and risks of OroCAM and other treatment options before deciding to use OroCAM. Use the lowest effective dose for the shortest duration consistent with individual response. Due to the pump sizes, dogs weighing less than 5.5 pounds (2.5 kg) cannot be accurately dosed. OroCAM should be administered once daily at a dose of 0.1 mg/kg (0.045 mg/lb). See Bottle/Pump Assembly Instructions for Veterinarians and Administration Instructions for Owners.
Particular care should be given with regard to the accuracy of dosing and to selecting the correct bottle size based on the weight of the dog. See the Dosing Table below.
Weight range (kg)
Weight range (lbs)
Bottle Size (mL)/ mg per spray
No. of sprays/ treatment
Dose amount (mg)
2.5 – 3.7
5.5 – 8.3
6 / 0.25
1
0.25
3.8 – 6.2
8.4 – 13.8
6 / 0.25
2
0.50
6.3 – 8.3
13.9 – 18.4
6 / 0.25
3
0.75
8.4 – 12.5
18.5- 27.6
11 / 0.50
2
1
12.6 – 18.8
27.7 – 41.5
11 / 0.50
3
1.50
18.9 – 27.1
41.6 – 59.7
33 / 1.075
2
2.15
27.2 – 40.5
59.8 – 89.1
33 / 1.075
3
3.23
40.6 – 54.0
89.2 – 118.8
33 / 1.075
4
4.3
54.1 – 57.2
118.9 – 125.8
33 / 1.075
5
5.38
Bottle/Pump Assembly Instructions for Veterinarians
Prior to dispensing, the pump should be screwed on to the bottle securely, the bottle gently shaken, and then the pump primed by actuating ten times (or until a fine spray appears) into an absorbent material. Once a bottle is assembled, the assembly date should be written on the bottle and the owner instructed to discard the bottle after 6 months. Wash hands after assembly.
Administration Instructions for Owners
OroCAM should be given according to your veterinarian’s instructions. Prior to each use, shake the bottle gently. If OroCAM is not used for two days or more, owners should re-prime with one spray into an absorbent material, or until a fine spray appears. In case of pump failure, wipe nozzle and then re-prime the pump. If a partial dose has been administered to the pet due to pump failure, do not redose; wait until the next dosing time to adminsiter OroCAM.
To administer OroCAM, grasp the corner of your dog’s mouth and gently pull it away from the gums, opening the cheek space. Place the tip of the applicator just inside the cheek space, directed towards the back of the cheek space. Holding the bottle and pump upright, fully depress the spray head taking special care to ensure no spray escapes from the mouth. If multiple sprays have been prescribed by your veterinarian, allow the pump to fully reflate before administering consecutive sprays. Immediately after administration of the spray, use a moist paper towel or tissue to clean the tip of the pump. Wash hands after administration of the product.
The end of the center tube should be covered by the fluid level. Once the fluid falls below the level of the center tube, sprays will not be adequate and the container should be replaced. There will be a residual volume of fluid at the bottom of the bottle which cannot be used.
Propoflo
Shake the vial thoroughly before opening.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Propofol is a white stable emulsion; do not use if there is evidence of separation of the phases. Do not use if there is evidence of excessive creaming or aggregation, if large droplets are visible, or if there are other forms of phase separation indicating that the stability of the product has been compromised. Slight creaming, which should disappear after shaking, may be visible upon prolonged standing. Do not use if particulate matter and discoloration are present.
Propofol contains no antimicrobial preservatives. Strict aseptic techniques must always be maintained during handling since the vehicle is capable of supporting the rapid growth of microorganisms. Failure to follow aseptic handling procedures may result in microbial contamination causing fever, infection/sepsis, and/or other life-threatening illness. Do not use if contamination is suspected.
Once propofol has been opened, vial contents should be drawn into sterile syringes; each syringe should be prepared for single patient use only.
Unused product should be discarded within 6 hours.
The emulsion should not be mixed with other therapeutic agents prior to administration. Administer by intravenous injection only.
For induction, propofol injection should be titrated against the response of the patient over 30-60 seconds or until clinical signs show the onset of anesthesia. Rapid injection of propofol (≤ 5 seconds) may be associated with an increased incidence of apnea2.
The average propofol induction dose rates for healthy dogs given propofol alone, or when propofol is preceded by a premedicant, are indicated in the table below. This table is for guidance only. The dose and rate should be based upon patient response.
Induction Dosage Guidelines Preanesthetic Propofol Induction Propofol Rate of Administration Dose mg/kg Seconds mg/kg/min mL/kg/min None 5.5 40 - 60 5.5 - 8.3 0.55 - 0.83 Acepromazine 3.7 30 - 50 4.4 - 7.4 0.44 - 0.74 Acepromazine / Oxymorphone 2.6 30 - 50 3.1 - 5.2 0.31 - 0.52Propofol doses and rates for the above premedicants were based upon the following average dosages. These doses may be lower than the label directions for their use as a single medication3,4.
Dose (mg/kg) Routes Acepromazine 0.060 IM, SC, IV Oxymorphone 0.090 IM, SC, IV Xylazine 0.33 IM, SCThe use of these drugs as preanesthetics markedly reduces propofol requirements. As with other sedative hypnotic agents, the amount of opioid and/or α-2 agonist premedication will influence the response of the patient to an induction dose of propofol.
In the presence of premedication, the dose of propofol may be reduced with increasing age of the animal. The dose of propofol should always be titrated against the response of the patient.
During induction, additional low doses of propofol, similar to those used for maintenance with propofol, may be administered to facilitate intubation or the transition to inhalant maintenance anesthesia.
A. Intermittent Propofol Injections: Anesthesia can be maintained by administering propofol in intermittent IV injections. Clinical response will be determined by the amount and the frequency of maintenance injections. The following table is provided for guidance:
Maintenance Dosage Guidelines Preanesthetic Propofol Maintenance Rate of Administration Dose mg/kg Seconds mg/kg/min mL/kg/min None 2.2 10 - 30 4.4 - 13.2 0.44 - 1.32 Acepromazine 1.6 10 - 30 3.2 - 9.6 0.32 - 0.96 Acepromazine / Oxymorphone 1.8 10 - 30 3.6 - 10.8 0.36 - 1.08Repeated maintenance doses of propofol do not result in increased recovery times or dosing intervals, indicating that the anesthetic effects of propofol are not cumulative.
B. Maintenance by Inhalant Anesthetics: Due to the rapid metabolism of propofol, additional low doses of propofol, similar to those used for maintenance with propofol, may be required to complete the transition to inhalant maintenance anesthesia.
Clinical trials using propofol have shown that it may be necessary to use a higher initial concentration of the inhalant anesthetic halothane than is usually required following induction using barbiturate anesthetics, due to rapid recovery from propofol5.
Sevoflurane Inhalant
Inspired Concentration: The delivered concentration of Sevoflurane should be known. Since the depth of anesthesia may be altered easily and rapidly, only vaporizers producing predictable percentage concentrations of sevoflurane should be used. Sevoflurane should be vaporized using a precision vaporizer specifically calibrated for sevoflurane. Sevoflurane contains no stabilizer. Nothing in the drug product alters calibration or operation of these vaporizers. The administration of general anesthesia must be individualized based on the patient’s response. WHEN USING SEVOFLURANE, PATIENTS SHOULD BE CONTINUOUSLY MONITORED AND FACILITIES FOR MAINTENANCE OF PATENT AIRWAY, ARTIFICIAL VENTILATION, AND OXYGEN SUPPLEMENTATION MUST BE IMMEDIATELY AVAILABLE.
Replacement of Desiccated CO2 Absorbents: When a clinician suspects that the CO2 absorbent may be desiccated, it should be replaced. An exothermic reaction occurs when sevoflurane is exposed to CO2 absorbents. This reaction is increased when the CO2 absorbent becomes desiccated (see PRECAUTIONS ).
Premedication: No specific premedication is either indicated or contraindicated with sevoflurane. The necessity for and choice of premedication is left to the discretion of the veterinarian. Preanesthetic doses for premedicants may be lower than the label directions for their use as a single medication.1
Induction: For mask induction using sevoflurane alone, inspired concentrations of up to 7% sevoflurane with oxygen are employed to induce surgical anesthesia in the healthy dog. These concentrations can be expected to produce surgical anesthesia in 3 to 14 minutes. Due to the rapid and dose dependent changes in anesthetic depth, care should be taken to prevent overdosing. Respiration must be monitored closely in the dog and supported when necessary with supplemental oxygen and/or assisted ventilation.
Maintenance: Sevoflurane may be used for maintenance anesthesia following mask induction using sevoflurane or following injectable induction agents. The concentration of vapor necessary to maintain anesthesia is much less than that required to induce it.
Surgical levels of anesthesia in the healthy dog may be maintained with inhaled concentrations of 3.7-4.0% sevoflurane in oxygen in the absence of premedication and 3.3-3.6% in the presence of premedication. The use of injectable induction agents without premedication has little effect on the concentrations of sevoflurane required for maintenance. Anesthetic regimens that include opioid, alpha2- agonist, benzodiazepine or phenothiazine premedication will allow the use of lower sevoflurane maintenance concentrations.
Veterinary Dextrose And Sodium Chloride
As directed by a veterinarian. Dosage is dependent upon the age, weight, and clinical condition of the patient as well as laboratory determinations.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
All injections in plastic containers are intended for intravenous administration using sterile equipment.
Additives may be incompatible. Complete information is not available.
Those additives known to be incompatible should not be used. Consult with veterinarian, if available. If, in the informed judgment of the veterinarian, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced.Do not store solutions containing additives.
Veterinary Lactated Ringers And Dextrose
As directed by a veterinarian. Dosage is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
All injections in plastic containers are intended for intravenous administration using sterile equipment.
Additives may be incompatible. Complete information is not available.Those additives known to be incompatible should not be used. Consult with veterinarian, if available. If, in the informed judgement of the veterinarian, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced.Do not store solutions containing additives.
Veterinary Lactated Ringers
As directed by a veterinarian. Dosage is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
All injections in plastic containers are intended for intravenous administration using sterile equipment.
Additives may be incompatible. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. If, in the informed judgment of the veterinarian, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives.
Veterinary Sodium Chloride
As directed by a veterinarian. Dosage is dependent upon the age, weight and clinical condition of the patient, as well as laboratory determinations.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
All injections in plastic containers are intended for intravenous administration using sterile equipment.
Additives may be incompatible. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. If, in the informed judgment of the veterinarian, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives.
Veterinary Lactated Ringers
The volume of solution needed will vary with the nature and duration of the arthroscopic procedure.
If desired, warm in overwrap to near body temperature in a water bath or oven heated to not more than 45° C.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
Veterinary Plasma Lyte 148
As directed by a veterinarian. Dosage is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
All injections in plastic containers are intended for intravenous administration using sterile equipment.
Additives may be incompatible. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. If, in the informed judgment of the veterinarian, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives.
Veterinary Sodium Chloride
The volume of solution needed will vary with the nature and duration of the procedure.
If desired, warm in overpouch to near body temperature in a water bath or oven heated to not more than 45°C/113°F.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
Veterinary Plasma Lyte A
As directed by a veterinarian. Dosage is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
All injections in plastic containers are intended for intravenous administration using sterile equipment.
Additives may be incompatible. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. If, in the informed judgment of the veterinarian, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives.
Pvp Iodine Prep Pad Medium And Large
Inspired Concentration: The delivered concentration of SevoFlo should be known. Since the depth of anesthesia may be altered easily and rapidly, only vaporizers producing predictable percentage concentrations of sevoflurane should be used. Sevoflurane should be vaporized using a precision vaporizer specifically calibrated for sevoflurane. Sevoflurane contains no stabilizer. Nothing in the drug product alters calibration or operation of these vaporizers. The administration of general anesthesia must be individualized based on the patient's response. WHEN USING SEVOFLURANE, PATIENTS SHOULD BE CONTINUOUSLY MONITORED AND FACILITIES FOR MAINTENANCE OF PATENT AIRWAY, ARTIFICIAL VENTILATION, AND OXYGEN SUPPLEMENTATION MUST BE IMMEDIATELY AVAILABLE.
Replacement of Desiccated CO2 Absorbents: When a clinician suspects that the CO2 absorbent may be desiccated, it should be replaced. An exothermic reaction occurs when sevoflurane is exposed to CO2 absorbents. This reaction is increased when the CO2 absorbent becomes desiccated (see PRECAUTIONS).
Premedication: No specific premedication is either indicated or contraindicated with sevoflurane. The necessity for and choice of premedication is left to the discretion of the veterinarian. Preanesthetic doses for premedicants may be lower than the label directions for their use as a single medication.1
Induction: For mask induction using sevoflurane alone, inspired concentrations of up to 7% sevoflurane with oxygen are employed to induce surgical anesthesia in the healthy dog. These concentrations can be expected to produce surgical anesthesia in 3 to 14 minutes. Due to the rapid and dose dependent changes in anesthetic depth, care should be taken to prevent overdosing. Respiration must be monitored closely in the dog and supported when necessary with supplemental oxygen and/or assisted ventilation.
Maintenance: SevoFlo may be used for maintenance anesthesia following mask induction using sevoflurane or following injectable induction agents. The concentration of vapor necessary to maintain anesthesia is much less than that required to induce it.
Surgical levels of anesthesia in the healthy dog may be maintained with inhaled concentrations of 3.7-4.0% sevoflurane in oxygen in the absence of premedication and 3.3-3.6% in the presence of premedication. The use of injectable induction agents without premedication has little effect on the concentrations of sevoflurane required for maintenance. Anesthetic regimens that include opioid, alpha2- agonist, benzodiazepine or phenothiazine premedication will allow the use of lower sevoflurane maintenance concentrations.
Propoflo 28
Administer by intravenous injection only. Shake the vial thoroughly before opening. Propofol is a white stable emulsion. Do not use if there is evidence of excessive creaming or aggregation, if large droplets are visible, or if there are other forms of phase separation indicating that the stability of the product has been compromised. Slight creaming, which should disappear after shaking, may be visible upon prolonged standing. Do not use if particulate matter and discoloration are present. Strict aseptic techniques must always be maintained during handling. Failure to follow aseptic handling procedures may result in microbial contamination causing fever, infection/sepsis, and/or other life threatening illness. Do not use if contamination is suspected. Once a vial is opened, the contents begin a 28-day shelf life. The opened vial should be labeled with “Date Opened” and “Use By” in the space provided. To avoid microbial overgrowth, the contents must be used within 28 days (4 weeks) of the date opened. The opened vial should be placed in a covered container, held at room temperature and used within the allotted 28 day timeframe. Refrigeration is not recommended. Any unused propofol remaining at the end of 28 days should be discarded. The emulsion should not be mixed with other therapeutic agents prior to administration. No specific preanesthetic is either indicated or contraindicated with propofol. The necessity for, choice of, as well as any necessary reduction of dose for the preanesthetic, is left to the discretion of the veterinarian. The dose of propofol is not affected by anticholinergic premedication.
Isoflo
Caution: Operating rooms should be provided with adequate ventilation to prevent the accumulation of anesthetic vapors.
Premedication: A premedication regimen, which may be employed depending upon the patient status, to avert excitement during induction, might include an anticholinergic, a tranquilizer, a muscle relaxant and a short-acting barbiturate.
Inspired Concentration: The delivered concentration of IsoFlo (isoflurane, USP) should be known. Isoflurane may be vaporized using a flow-through vaporizer specifically calibrated for isoflurane. Vaporizers delivering a saturated vapor which then is diluted (e.g. Verni-trol® vaporizer) also may be used. The delivered concentration from such a vaporizer may be calculated using the formula:
% isoflurane = 100 PVFV / FT(PA-PV)
Where: PA = Pressure of atmosphere PV = Vapor pressure of isoflurane FV = Flow of gas through vaporizer (mL/min) FT = Total gas flow used (mL/min)
Isoflurane contains no stabilizer. Nothing in the drug product alters calibration or operation of these vaporizers.
Induction:
Horses: Inspired concentrations of 3.0 to 5.0% isoflurane alone with oxygen following a barbiturate anesthetic induction are usually employed to induce surgical anesthesia in the horse.
Dogs: Inspired concentrations of 2.0 to 2.5% isoflurane alone with oxygen following a barbiturate anesthetic induction are usually employed to induce surgical anesthesia in the dog.
These concentrations can be expected to produce surgical anesthesia in 5 to 10 minutes.
Maintenance: The concentration of vapor necessary to maintain anesthesia is much less than that required to induce it.
Horses: Surgical levels of anesthesia in the horse may be sustained with a 1.5 to 1.8% concentration of isoflurane in oxygen.
Dogs: Surgical levels of anesthesia in the dog may be sustained with a 1.5 to 1.8% concentration of isoflurane in oxygen.
The level of blood pressure during maintenance is an inverse function of isoflurane concentration in the absence of other complicating problems. Excessive decreases, unless related to hypovolemia, may be due to depth of anesthesia and in such instances may be corrected by lightening the level of anesthesia.
Recovery from isoflurane anesthesia is typically uneventful.2
Paccal Vet-ca1
Always provide the Client Information Sheet to the dog owner with each dose administration.
Administer Paccal Vet-CA1 at 150 mg/m2 body surface area (BSA) intravenously over 15-30 minutes, once every three weeks for up to four doses. Dose reductions of 10 mg/m2 or dose delays may be used to manage adverse reactions.Reconstitution and administration of Paccal Vet-CA1
Paccal Vet-CA1 is supplied as a sterile powder for reconstitution before use. After reconstitution the solution contains 1 mg of paclitaxel/mL. Paccal Vet-CA1 should be protected from light throughout the preparation process. Paccal Vet-CA1 preparation should be done with aseptic technique and the reconstituted product should be used immediately.
Obtain the desired number of vials from the refrigerator. The powder should be greenish-yellow to yellow. In case of discoloration, discard the vial. Let the vials stand protected from light at room temperature for approximately 20 to 30 minutes. The room temperature should not exceed 25°C (77°F). Using a sterile syringe, inject 60 mL of Lactated Ringer’s solution, USP, into a vial of Paccal Vet-CA1. Pressure must be equilibrated by a needle or vial spike before injection. The Lactated Ringer’s solution should be injected slowly, directed onto the inside wall of the vial and not directly onto the powder as this will result in foaming. Gently swirl the vial by hand for 20 to 30 seconds. Protect from light and allow the vial to stand for 3 to 5 minutes. Gently and slowly swirl and/or invert the vial until the powder is completely dissolved. Do not shake, this will result in foaming. If foam develops, allow the solution to stand for several minutes. Reconstitution can continue even if all of the foam has not dissipated. If undissolved product is present, the vial should be placed on a shaker and rotated for up to 15 minutes, while protecting from light. The solution should be clear and greenish-yellow without visible precipitates. If precipitates or discoloration (orange-reddish) are observed, the solution should be discarded. Inject the appropriate amount of reconstituted Paccal Vet-CA1 into an empty, sterile, EVA (ethyl vinyl acetate) infusion bag. Protect the reconstituted product in the EVA infusion bag from light. The reconstituted product should be used immediately. Administer Paccal Vet-CA1 intravenously over 15-30 minutes.Compatibility of administration sets containing DEHP (di(2-ethylhexyl) phthalate) has not been demonstrated.
Vital Hgh Immune Booster
As directed by a veterinarian. Dosage is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
All injections in plastic containers are intended for intravenous administration using sterile equipment.
Additives may be incompatible. Complete information is not available. Those additives known to be incompatible should not be used. Consult with veterinarian, if available. If, in the informed judgment of the veterinarian, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced.Do not store solutions containing additives.
Sign Up for a Free Account